Changes in 2'-deoxycytidine Levels in Various Tissues of Tumor-bearing Mice

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Aug 8

PMID 22870101

Citations 1

Authors

Ayano Iwazaki

Kimie Imai

Kunio Nakanishi

Masanori Yoshioka

Affiliations

Soon will be listed here.

Abstract

The nucleoside 2'-deoxycytidine (dCyd) increases in the plasma of cancer patients with poor prognoses. 5-fluorouracil (5FU) is one of the anti-cancer agents used in chemotherapy for patients whose plasma dCyd is elevated. We examined the free dCyd level in various tissues of mice, with and without tumors, and in mice with and without the administration of 5FU or of dCyd, and investigated the effects of dCyd in tumor-bearing animals. SP2/0-Ag14 mouse myeloma cells were transplanted subcutaneously into mice and 5FU or dCyd was administered intraperitoneally. Free dCyd was measured in blood and tissues by HPLC at two time points, once when mouse body weight was maximally decreased (1 day after the last administration of 5FU, day 16) and again when it returned to control level at 1 week after the last 5FU treatment (day 22). Results showed that in tumor-bearing mice, the level of dCyd (per g wet weight) increased in the spleen. The change in liver weight caused by the administration of 5FU correlated with the level of dCyd in the liver. Notably, the relative tumor volume and tumor weight was decreased in dCyd-treated animals in comparison with controls. In conclusion, the levels of dCyd were markedly altered in the tissues of the reticuloendothelial and lymphatic systems, such as liver and spleen, and dCyd apparently had the ability to inhibit tumor growth in the body.

Citing Articles

Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer.

Mendes R, Graca G, Silva F, Guerreiro A, Gomes-Alves P, Serpa J Cancers (Basel). 2022; 14(18).

PMID: 36139619 PMC: 9496731. DOI: 10.3390/cancers14184460.

References

OSOGOE B, Tyler R, EVERETT N . The patterns of labeling of germinal-center cells with tritiated deoxycytidine. J Cell Biol. 1973; 57(1):215-20. PMC: 2108944. DOI: 10.1083/jcb.57.1.215. View

Muramatsu M, Sankaranand V, Anant S, Sugai M, Kinoshita K, Davidson N . Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999; 274(26):18470-6. DOI: 10.1074/jbc.274.26.18470. View

Iwazaki A, Yoshioka M . 2'-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells. Biol Pharm Bull. 2010; 33(6):1024-7. DOI: 10.1248/bpb.33.1024. View

Miwa M, Eda H, Ura M, Ouchi K, Keith D, Foley L . High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine. Clin Cancer Res. 1998; 4(2):493-7. View

Okazaki I, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K . Constitutive expression of AID leads to tumorigenesis. J Exp Med. 2003; 197(9):1173-81. PMC: 2193972. DOI: 10.1084/jem.20030275. View

SCHNEIDER W, BEHKI R . PHOSPHORUS COMPOUNDS IN ANIMAL TISSUES. VII. ENZYMATIC FORMATION OF DEOXYCYTIDINE DIPHOSPHATE CHOLINE AND LECITHIN BY TISSUE HOMOGENATES. J Biol Chem. 1963; 238:3565-71. View

OSOGOE B, Ueki A . A radioautographic study of the utilization of deoxycytidine for the formation of deoxyribonucleic acid-thymine in lymphocytes. J Cell Biol. 1970; 46(2):403-5. PMC: 2108018. DOI: 10.1083/jcb.46.2.403. View

Chen E, Johnson 2nd E, Vetter S, Mitchell B . Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest. 1995; 95(4):1660-8. PMC: 295671. DOI: 10.1172/JCI117841. View

Chan T, Lakhchaura B, Hsu T . Differences in deoxycytidine metabolism in mouse and rat. Biochem J. 1983; 210(2):367-71. PMC: 1154233. DOI: 10.1042/bj2100367. View

10.

Berlinger W, Stene R, Spector R . Plasma and cerebrospinal fluid nucleosides and oxypurines in acute liver failure. J Lab Clin Med. 1987; 110(2):137-44. View

11.

Rossi L, Serafini S, Schiavano G, Casabianca A, Vallanti G, Chiarantini L . Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine. Biochem J. 1999; 344 Pt 3:915-20. PMC: 1220716. View

12.

Hapke D, Stegmann A, Mitchell B . Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 1996; 56(10):2343-7. View

13.

Harris R, Petersen-Mahrt S, Neuberger M . RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell. 2002; 10(5):1247-53. DOI: 10.1016/s1097-2765(02)00742-6. View

14.

Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T . Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102(5):553-63. DOI: 10.1016/s0092-8674(00)00078-7. View

15.

Moyer J, Malinowski N, Ayers O . Salvage of circulating pyrimidine nucleosides by tissues of the mouse. J Biol Chem. 1985; 260(5):2812-8. View

16.

Kotani A, Okazaki I, Muramatsu M, Kinoshita K, Begum N, Nakajima T . A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci U S A. 2005; 102(12):4506-11. PMC: 555529. DOI: 10.1073/pnas.0500830102. View

17.

Yoshioka M, Abu-Zeid M, Kubo T . Identification of a previously unknown compound as 2'-deoxycytidine found in the plasma of breast cancer patients under combined chemotherapy. Biol Pharm Bull. 1994; 17(2):169-72. DOI: 10.1248/bpb.17.169. View